<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Methylprednisolone on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/methylprednisolone/</link><description>Recent content in Methylprednisolone on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Sun, 28 Jun 2026 05:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/methylprednisolone/index.xml" rel="self" type="application/rss+xml"/><item><title>Early Methylprednisolone Pulses and Long-Term Damage in Active SLE</title><link>https://rheumatologydigest.org/posts/mp-pulses-sle-damage/</link><pubDate>Sun, 28 Jun 2026 05:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/mp-pulses-sle-damage/</guid><description>A propensity-score analysis of the Lupus–Cruces–Bordeaux inception cohort: early (first-year) methylprednisolone pulses were associated with a ~40% reduction in long-term irreversible damage or death in active SLE, with benefit concentrated in moderate–severe disease — likely reflecting an MP-anchored low-steroid strategy rather than the molecule alone.</description></item></channel></rss>